Thomas L. Perry

10.6k total citations · 2 hit papers
185 papers, 8.4k citations indexed

About

Thomas L. Perry is a scholar working on Clinical Biochemistry, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Thomas L. Perry has authored 185 papers receiving a total of 8.4k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Clinical Biochemistry, 55 papers in Molecular Biology and 51 papers in Cellular and Molecular Neuroscience. Recurrent topics in Thomas L. Perry's work include Metabolism and Genetic Disorders (58 papers), Neuroscience and Neuropharmacology Research (36 papers) and Amino Acid Enzymes and Metabolism (31 papers). Thomas L. Perry is often cited by papers focused on Metabolism and Genetic Disorders (58 papers), Neuroscience and Neuropharmacology Research (36 papers) and Amino Acid Enzymes and Metabolism (31 papers). Thomas L. Perry collaborates with scholars based in Canada, United States and United Kingdom. Thomas L. Perry's co-authors include Shirley Hansen, V. Wee Yong, David V. Godin, Karen L. Jones, Stephen J. Kish, James M Wright, Janet Kennedy, K. Berry, Lynne MacDougall and C. C. Mok and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Thomas L. Perry

182 papers receiving 7.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Huntington's Chorea

1973 644 citations Thomas L. Perry, Shirley Hansen et al. profile →
Parkinson's disease: A disorder due to nigral glutathione deficiency?

1982 615 citations Thomas L. Perry, Shirley Hansen et al. profile →

Peers

Countries citing papers authored by Thomas L. Perry

Since Specialization

Citations

This map shows the geographic impact of Thomas L. Perry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas L. Perry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas L. Perry more than expected).

Fields of papers citing papers by Thomas L. Perry

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas L. Perry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas L. Perry. The network helps show where Thomas L. Perry may publish in the future.

Co-authorship network of co-authors of Thomas L. Perry

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas L. Perry. A scholar is included among the top collaborators of Thomas L. Perry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas L. Perry. Thomas L. Perry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reducing prescribing cascades 2025 ·African Journal of Primary Health Care & Family Medicine ·Aaron M Tejani, Thomas L. Perry	0
2	Minimising inhaled corticosteroids for COPD 2024 ·African Journal of Primary Health Care & Family Medicine ·(unknown), Thomas L. Perry, Ken Bassett	0
3	How to navigate drug shortages with patients in primary care 2024 ·Canadian Family Physician ·(unknown), (unknown), Thomas L. Perry	1
4	Restoring mortality data in the FOURIER cardiovascular outcomes trial of evolocumab in patients with cardiovascular disease: a reanalysis based on regulatory data 2022 ·BMJ Open ·Juan Erviti, James M Wright, Ken Bassett, Mohamed Ben‐Eltriki, (unknown), Luis Carlos Saiz, Leire Leache, Marta Gutiérrez‐Valencia, Thomas L. Perry	14
5	Rethinking the Appraisal and Approval of Drugs for Fracture Prevention 2017 ·Frontiers in Pharmacology ·Juan Erviti, Javier Gorricho, Luis Carlos Saiz, Thomas L. Perry, James M Wright	7
6	Overdiagnosis of bone fragility in the quest to prevent hip fracture 2015 ·BMJ ·Teppo L. N. Järvinen, Karl Michaëlsson, Jarkko Jokihaara, Gary S. Collins, Thomas L. Perry, Barbara Mintzes, Vijaya M Musini, Juan Erviti, Javier Gorricho, J. Wright, Harri Sievänen	75
7	Information for Physicians and Pharmacists About Drugs That Might Cause Dry Mouth: A Study of Monographs and Published Literature 2013 ·Drugs & Aging ·Caroline T. Nguyen, Michael I. MacEntee, Barbara Mintzes, Thomas L. Perry	9
8	Comparison of the oscillometric blood pressure monitor (BPM-100 Beta ) with the auscultatory mercury sphygmomanometer 2001 ·Blood Pressure Monitoring ·(unknown), Thomas L. Perry, James M Wright	72
9	Validation of a new algorithm for the BPM-100 electronic oscillometric office blood pressure monitor 2001 ·Blood Pressure Monitoring ·James M Wright, (unknown), Thomas L. Perry, (unknown), (unknown), (unknown), (unknown)	92
10	Amyotrophic lateral sclerosis: Amino acid levels in plasma and cerebrospinal fluid 1990 ·Annals of Neurology ·Thomas L. Perry, Charles Krieger, Shirley Hansen, Andrew Eisen	134
11	Mitochondrial encephalomyopathy with associated aminoacidopathy in a male sibship 1989 ·The Journal of Pediatrics ·Frances Booth, J. C. Haworth, Louise A. Dilling, Thomas L. Perry, Cheryl R. Greenberg, L.E. Seargeant, Andrew M. Penn, William J. Rhead	3
12	β-N-Methylamino-l-alanine 1989 ·Journal of the Neurological Sciences ·Thomas L. Perry, Catherine Bergeron, (unknown), Shirley Hansen	63
13	Brain choline acetyltransferase reduction in dominantly inherited olivopontocerebellar atrophy 1987 ·Annals of Neurology ·Stephen J. Kish, Robert D. Currier, Lawrence J. Schut, Thomas L. Perry, (unknown)	20
14	Glucuronidation of the Enantiomers of E‐10‐Hydroxynortriptyline in Human and Rat Liver Microsomes 1987 ·Pharmacology & Toxicology ·Étienne Dumont, Christer von Bahr, Thomas L. Perry, Leif Bertilsson	16
15	α-Tocopherol and β-carotene do not protect marmosets against the dopaminergic neurotoxicity of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 1987 ·Journal of the Neurological Sciences ·Thomas L. Perry, V. Wee Yong, Shirley Hansen, Karen L. Jones, Catherine Bergeron, James G. Foulks, James M Wright	36
16	Lactic acidosis in three sibs due to defects in both pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase complexes. 1976 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·J. C. Haworth, Thomas L. Perry, John P. Blass, Shirley Hansen, Nadine Urquhart	52
17	Effects of 3-acetylpyridine on putative neurotransmitter amino acids in rat cerebellum 1976 ·Brain Research ·Thomas L. Perry, (unknown), (unknown), (unknown), (unknown), (unknown)	34
18	Antibiotic abuse: the testimony of medical students. 1975 ·PubMed ·Thomas L. Perry	1
19	URINARY EXCRETION OF AMINES IN NORMAL CHILDREN 1962 ·PEDIATRICS ·Thomas L. Perry, Kenneth N.F. Shaw, Dorothy Walker, Dorothy von Redlich	64
20	Treatment of tuberculous meningitis in children 1952 ·The Journal of Pediatrics ·Thomas L. Perry	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact